A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

General Information

Summary The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Clinical trials phase Phases 1/2
Start date (estimated) 2023-05-16
End date (estimated) 2026-05-31
Clinical feature
Label type 1 diabetes mellitus
Link http://purl.obolibrary.org/obo/DOID_9744
Description A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT05791201
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05791201
EudraCT number 2022-003318-35
Other study identifiers
Name VX22-264-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT05791201
Public contact
Email medicalinfo@vrtx.com
Public email medicalinfo@vrtx.com
Last name Medical Information
Phone +1 617-341-6777
United States
Sponsors Vertex Pharmaceuticals Incorporated


Which differentiated cell type is used
Label progenitor cell of endocrine pancreas
Link http://purl.obolibrary.org/obo/CL_0002351
Description A progenitor cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1.


Recruitment Status Recruiting
Estimated number of participants 17